Form 4: BioXcel Therapeutics Executive VP Vincent O'Neill Reports Stock Sales and RSU Conversions
SEC Form 4
Executive Vice President of BioXcel Therapeutics, Vincent O'Neill, reports the conversion of Restricted Stock Units (RSUs) into common stock and subsequent sale of shares, according to a Form 4 filing.
Summary
- Vincent O'Neill, Executive Vice President of BioXcel Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On March 14, 2024, 521 shares were acquired through the conversion of Restricted Stock Units (RSUs) and then disposed of.
- On March 15, 2024, 2,250 shares were acquired through the conversion of RSUs and then disposed of.
- On April 4, 2024, 165 shares were sold at a price of $2.6211 per share.
- Following these transactions, O'Neill directly owns 5,408 shares of BioXcel Therapeutics common stock.
- The sales on April 4, 2024, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023.
- O'Neill also holds 4,169 RSUs from a grant on March 14, 2022, and 6,750 RSUs from a grant on March 15, 2023, which vest quarterly.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of stock transactions by an executive, with no inherently positive or negative implications for the company's overall prospects.
Key Dates
| Date | Description |
|---|---|
| March 14, 2022 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| March 15, 2023 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| December 15, 2023 | Reporting Person adopted a Rule 10b5-1 trading plan |
| March 14, 2024 | 521 shares acquired via RSU conversion and disposed of |
| March 15, 2024 | 2,250 shares acquired via RSU conversion and disposed of |
| April 04, 2024 | 165 shares sold at $2.6211 |
| April 08, 2024 | Date of Form 4 filing |
Keywords
Form 4, BioXcel Therapeutics, BTAI, Vincent O'Neill, RSU, Stock Sale, Beneficial Ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.